- Home
- IFN vs LRMR Comparison
IFN vs LRMR Comparison
Compare IFN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IFN | LRMR |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.6M | 455.8M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IFN | LRMR |
|---|---|---|
| Price | $11.47 | $4.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 124.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.72 | $2.72 |
| 52 Week High | $15.47 | $6.42 |
Technical Indicators
Market Signals| Indicator | IFN | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 37.13 | 50.38 |
| Support Level | $11.40 | $2.98 |
| Resistance Level | $11.79 | $4.21 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 2.91 | 25.23 |
Price Performance
Historical ComparisonAbout IFN India Fund Inc. (The)
India Fund Inc is a non-diversified closed-end management investment company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.